Neutralize the Neutrophils! Neutrophil β1/β2 Integrin Activation Contributes to JAK2-V617F-driven Thrombosis

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2018 Aug 28

PMID 30148454

Citations 2

Authors

Stephen T Oh

Affiliations

Soon will be listed here.

Citing Articles

Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.

Torres D, Paes J, da Costa A, Malheiro A, Silva G, de Souza Mourao L Biomolecules. 2022; 12(2).

PMID: 35204792 PMC: 8961666. DOI: 10.3390/biom12020291.

Neutrophil Death in Myeloproliferative Neoplasms: Shedding More Light on Neutrophils as a Pathogenic Link to Chronic Inflammation.

Markovic D, Maslovaric I, Djikic D, cokic V Int J Mol Sci. 2022; 23(3).

PMID: 35163413 PMC: 8836089. DOI: 10.3390/ijms23031490.

References

Hultcrantz M, Bjorkholm M, Dickman P, Landgren O, Derolf A, Kristinsson S . Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study. Ann Intern Med. 2018; 168(5):317-325. PMC: 7533681. DOI: 10.7326/M17-0028. View

De Stefano V, Za T, Rossi E, Vannucchi A, Ruggeri M, Elli E . Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol. 2010; 85(2):97-100. DOI: 10.1002/ajh.21593. View

Tefferi A, Elliott M . Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007; 33(4):313-20. DOI: 10.1055/s-2007-976165. View

Barbui T, Masciulli A, Marfisi M, Tognoni G, Finazzi G, Rambaldi A . White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015; 126(4):560-1. DOI: 10.1182/blood-2015-04-638593. View

Sands B . Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions. Dig Dis. 2017; 35(1-2):13-20. DOI: 10.1159/000449077. View

Ball S, Thein K, Maiti A, Nugent K . Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms. J Thromb Thrombolysis. 2018; 45(4):516-528. DOI: 10.1007/s11239-018-1623-4. View

Edelmann B, Gupta N, Schnoeder T, Oelschlegel A, Shahzad K, Goldschmidt J . JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. J Clin Invest. 2018; 128(10):4359-4371. PMC: 6159978. DOI: 10.1172/JCI90312. View

Barbui T, Carobbio A, Rambaldi A, Finazzi G . Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?. Blood. 2009; 114(4):759-63. PMC: 2716019. DOI: 10.1182/blood-2009-02-206797. View

Mesa R, Jamieson C, Bhatia R, Deininger M, Fletcher C, Gerds A . NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Netw. 2017; 15(10):1193-1207. DOI: 10.6004/jnccn.2017.0157. View

10.

Stein B, Gotlib J, Arcasoy M, Nguyen M, Shah N, Moliterno A . Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw. 2015; 13(4):424-34. PMC: 8161684. DOI: 10.6004/jnccn.2015.0058. View

11.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D . Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2012; 368(1):22-33. DOI: 10.1056/NEJMoa1208500. View

12.

Wolach O, Sellar R, Martinod K, Cherpokova D, McConkey M, Chappell R . Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018; 10(436). PMC: 6442466. DOI: 10.1126/scitranslmed.aan8292. View

13.

Gupta N, Edelmann B, Schnoeder T, Saalfeld F, Wolleschak D, Kliche S . JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1. Leukemia. 2017; 31(5):1223-1226. PMC: 5420787. DOI: 10.1038/leu.2017.26. View

14.

Schwab N, Schneider-Hohendorf T, Wiendl H . Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis. Int Immunol. 2014; 27(1):47-53. DOI: 10.1093/intimm/dxu096. View

15.

Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R . Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2006; 109(6):2446-52. DOI: 10.1182/blood-2006-08-042515. View

16.

Kroll M, Michaelis L, Verstovsek S . Mechanisms of thrombogenesis in polycythemia vera. Blood Rev. 2015; 29(4):215-21. PMC: 4466074. DOI: 10.1016/j.blre.2014.12.002. View